Pathogenesis of Churg-Strauss syndrome: Recent insights

Autoimmunity

Volumn 42, Issue 4, 2009, Pages 376-379

  Zwerina, Jochen ^a   Axmann, Roland ^a   Jatzwauk, Maria ^a   Sahinbegovic, Enijad ^a   Polzer, Karin ^a   Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

ANCA; ChurgStrauss syndrome; Eotaxin 3

Indexed keywords

AUTOANTIBODY; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; EOTAXIN 3; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; MONTELUKAST; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ASTHMA; CELL INFILTRATION; CELL MIGRATION; CELLULAR IMMUNITY; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE EXACERBATION; EOSINOPHIL; EOSINOPHILIA; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSTIMULATION; NONHUMAN; PROTEIN FUNCTION; SHORT SURVEY; TH2 CELL;

ANIMALS; CHEMOKINES, CC; CHURG-STRAUSS SYNDROME; HUMANS; INTERLEUKIN-5; MICE;

EID: 70749113067     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930902832348     Document Type: Short Survey

References (20)

1. Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007;19:25-32.
2. Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: A multicenter, prospective, randomized, openlabel study of seventy-two patients. Arthritis Rheum 2008;58: 586-594.
3. Cohen P, Pagnoux C, Mahr A, Arene JP, Mouthon L, et al. Churg- Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007;57:686-693.
4. Hellmich B, Ehlers S, Csernok E, Gross WL. Update on the pathogenesis of Churg -Strauss syndrome. Clin Exp Rheumatol 2003;21:S69-S77.
5. Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, et al. ANCA and the Churg-Strauss syndrome. Ann Intern Med 2005;143:632-638.
6. Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: A case-crossover study. Thorax 2008;63:677-682.
7. Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, et al. Prevalence and clinical significance of ANCA in Churg- Strauss syndrome. Arthritis Rheum 2005;52:2926-2935.
8. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, et al. ANCA specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-963.
9. Zwerina J, Axmann R, Manger B, Schett G. The emergence of antineutrophil cytoplasmic antibodies may precede clinical onset of Churg-Strauss syndrome. Arthritis Rheum 2009; 60(2):626-627.
10. Guilpain P, Auclair JF, Tamby MC, Servettaz A,Mahr A, et al. Serum eosinophil cationic protein: A marker of disease activity in Churg-Strauss syndrome. Ann NY Acad Sci 2007;1107: 392-399.
11. Kiene M, Csernok E, Muller A, Metzler C, Trabandt A, et al. Elevated IL-4 and IL-13 production by TC lines from patients with Churg-Strauss syndrome. Arthritis Rheum 2001;44: 469-473.
12. Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, et al. Rituximab is effective in the treatment of refractory Churg- Strauss syndrome and is associated with diminished TC IL-5 production. Rheumatology (Oxford) 2008;47:1104-1105.
13. Shiota Y, Matsumoto H, Kanehisa Y, Tanaka M, Kanazawa K, et al. Serum IL-5 levels in a case with allergic granulomatous angiitis. Intern Med 1997;36:709-711.
14. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE,Weller PF, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358: 1215-1228.
15. Pease JE. Asthma, allergy and chemokines. Curr Drug Targets 2006;7:3-12.
16. Fulkerson PC, Fischetti CA, McBride ML, Hassman LM, Hogan SP, et al. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci USA 2006;103: 16418-16423.
17. Rothenberg ME, Maclean JA, Pearlman E, Luster AD, Leder P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med 1997;185:785-790.
18. Berkman N, Ohnona S, Chung FK, Breuer R. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol 2001;24:682-687.
19. Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006;116: 536-547.
20. Polzer K, KaronitschT, NeumannT, Eger G, Haberler C, et al. Eotaxin-3 is involved in Churg-Strauss syndrome-A serum marker closely correlating with disease activity. Rheumatology (Oxford) 2008;47:804-808.